



Appendix 1

MEDEZE's Key Milestone



Important events and developments during the year

In 2024, the Group experienced significant developments and events. as follows;

On October 15, 2024
Listed on the SET



"MEDEZE" started trading on the first day of trading on the Stock Exchange of Thailand. Continue to expand the business of hair follicle cells and robotic cell storage systems. Expand the profit base and create future growth opportunities. Reinforcing industry leadership

On November 21, 2024
Awards of Honor



"MEDEZE" wins the "ACES Award" for Industry Champions of the Year, setting an outstanding standard in Stem Cell Banking. Reinforce its position as one of the leaders in the development of outstanding Stem Cell Bank both in Thailand and in the region organized by MORS Group

On December 3, 2024
Signed a contract



"MEDEZE" signed a contract with "Shibuya Corporation" in Japan. One of the technology leaders in purchasing an automated cell culture system, a smart system to empower the cell bank of the future. Expected to be delivered June 2026 reinforces one of the leading developers and offers outstanding stem cell solutions in Thailand and the region

On December 18, 2024
Approved the establishment of a new subsidiary



"MEDEZE" has approved the establishment of a new subsidiary. In the name of "MEDEZE Hair Renaissance". Expanded hair follicle cell business to the "Health and Wellness" market with a registered capital of 100 million baht. To start commencing in the first quarter of 2025, aiming to create innovation in health. To response to the needs of a continuously growing market

On December 23, 2024
Selected for FTSE SET Shariah Index




"MEDEZE" Being selected for the FTSE SET Shariah Index is another milestone. MEDEZE has been selected as one of the new securities of the FTSE SET Shariah Index prepared by the Stock Exchange of Thailand in collaboration with FTSE Russell.




Stem Cell Banking Service

For new born



Cord Blood Stem Cell Banking

Cell Banking for Hematopoietic Stem Cell ("HSC") from cord blood which may develop to any blood cell




Placenta or Cord Tissue Stem Cell Banking

Cell Banking for Mesenchymal Stem Cell ("MSC") from cord tissue which may develop to any organ in body




For Everyone



Adipose Stem Cell Banking

Cell Banking for Mesenchymal Stem Cell ("MSC") from Fat which may develop to any organ in body




Hair Follicle Stem Cell Banking

Cell Banking for Hair Follicle

NK Cell Natural Killer Cell Service

Natural Killer Cell ("NK Cell") is type of white blood cell which represent the first line of defense in immunity system in body



NK
Test

Masuyama
Test

NK
Service

NK's related services can be divided into 3 sub-services;

1. Testing technique invented by Professor Masuyama from Japan. To know what kind of immunity is called good immunity. Including testing of NK cell activity and numbers of NK cell.
2. Testing to measure the activity of NK cell which represent the strength of immunity system
3. Service to measure NK activity in vary dimensions which including NK multiplication service

Thailand's Exclusive



MEDEZE using
Osaki-Method in
Masuyama Test and
NK Service which is
the technique
invented by **Junichi
Masuyama, M.D.,
Ph.D.** from Japan

1 Thailand's Leader in Medical Innovation

MEDEZE provide service with advance technology such as **AutoXpress** and **Quantum Machine** in stem cell process

AXP AutoXpress

- **MEDEZE** is the only company using AXP AutoXpress to process Cord Blood Stem Cell in Thailand



- ✓ Automatic system
- ✓ Lower processing time
- ✓ Reduce human error
- ✓ Lower contamination risk



Quantum Machine

- **MEDEZE** use Quantum Machine in stem cell multiplication process to reduce multiplication time and increase process efficiency



Global Standard

- **MEDEZE** provide service with high standard laboratory and banking storage room



Laboratory with Clean Room Class 100 Standard

Stem Cell Banking storage room with AABB global standard



2 Provide Services with Global Standard

MEDEZE Provides global standard on key operation function such as **laboratory** and **Cell banking room**



AABB Accredited

AABB standards incorporate both technical and quality systems standards to ensure that all facets about blood bank system are reviewed



Accredited Cell Storage Room



Laboratory with Clean Room Class 100



NEBB Standard

Cleanroom Performance Testing verifies environmental pollutants, per standards and specifications, are not present. NEBB certification demonstrates expertise in the required standards and guidelines



ISO 22716:2007

Guidance to documenting and regulating the production, control, storage, and shipment of cosmetic products.



GMP

Good Manufacturing Practice



ISO 9001

Globally recognized standard for quality management. It helps organizations of all sizes and sectors to improve their performance, meet customer expectations and demonstrate their commitment to quality

2 Provide Services with Global Standard

FROST & SULLIVAN

Received multiple years award from Frost & Sullivan; an global leader consulting firm

2017

Thailand
Stem Cell
Banking Growth
Excellence
Leadership Award

2018

Thailand
Stem Cell
Banking Growth
Excellence
Leadership Award

2019

**Thailand and
Southeast Asia**
Stem Cell
Banking Growth
Excellence
Leadership Award

2020

**Thailand and
Southeast Asia**
Stem Cell
Banking Growth
Excellence
Leadership Award

2021

Southeast Asia
Stem Cell
Banking Growth
Excellence
Leadership Award

2023

Southeast Asia
Stem Cell
Banking Growth
Excellence
Leadership Award

2024

Southeast Asia
Stem Cell
Banking Growth
Excellence
Leadership Award



MEDEZE wins “ACES Award” for outstanding standard creation in stem cell care

In 2024 “MEDEZE Group” wins “ACES Award for Industry Champions of the Year” reaffirming its position as one of the leaders in developing outstanding stem cell banks in Thailand and the region.




3 MEDEZE Operates in High Growth Industry

Stem cell and NK cell industries are the medical technology industries of the future which has high growth.

Market value of the global Stem Cell industry in 2024F - 2032F

Unit : Billions of US dollars



Source: Fortune business insights - Stem Cells Market Size, Share & Industry Analysis , year 2024

Factors supporting the growth of the stem cell industry include:



The rise of stem cell research



The increase in the middle-income group



Expanding investment in private hospital business




Entering Thailand's aging society



Market value of the global NK Cell industry in 2024F - 2032F

Unit : Billions of US dollars




Source: The IMARC Group - Natural Killer Cells Therapeutics Market, year 2023

Factors supporting the growth of the stem cell industry include:




The trend of increased health care comes from awareness of the importance of immune cells due to the COVID-19 outbreak situation, etc.



The rise of research, The increase in middle income group, Expanding hospital and aging society are factors supporting stem cell industry

1. The rise of stem cell research



Source: Centers for Disease Control and Prevention - United States Cancer Statistics

- The growth of the Stem Cells industry can be estimated by tracking the increasing volume of research related to stem cell applications.
- From the American National Library of Medicine, Reports of studies on stem cell applications have grown from 800 studies in 2020 to 6,400 studies during 2022.

3. Expanding investment in private hospital business




Number of hospitals and patient beds **+2,000** beds in 2022



Source: Krungsri Research

- The private hospital business is constantly opening new branches and expanding the number of beds to accommodate patients, and will increase the opportunity to reach more middle and high-income customers.
- This will increase the opportunity to reach middle to high-income customers, which are the main customer groups of businesses in the stem cell industry


2. The increase in the middle-income group



Source: Krungsri Research - Business/Industry Trends 2020 - 2022: Private Hospital Business

- The proportion of middle-income earners continues to grow, which is the main customer group in the stem cell banking industry.

3. Entering Thailand's aging society




Source: Thai Elderly Research and Development Institute Foundation

- Thailand is becoming a Super-Aged Society, with people aged 60 years and over making up more than 28% of the Thai population in 2031 from 20% in 2022.
- Such factors will support the demand for anti-aging and regenerative medicine and the storage of more stem cells for the general public.

4 Solid Customer Base & Hospitals Network

More than **228+** hospital partners nation wide and more than **10,000+** trusted customers



International Presence

5 countries in South East Asia



Vietnam



Indonesia



Singapore



Cambodia




Myanmar

Provide variety services to satisfy customer in every generation


Stem cell Service

Cord Blood




- Both cord blood and placenta stem cell can only collect when first born

Cord Tissue



- Ideal service for parents who would like to secure the child's future

Adipose



- Stem cell collect from fat suitable for all age customers


Hair Follicle



- Ideal service for all age customers who would like

NK Cells Service

NK Test / Masuyama Test / NK Service



- Service for every people in all generation to monitor immunity system capability

Newborn baby

Grown Up & Elderly

Appendix 2

Details of Holdings of Relevant Securities by the Relevant Persons as at the Offer Announcement Date

No.	Name	Direct Interest		Deemed Interest ¹	
		No. of Shares	% ²	No. of Shares	% ²
1	Offeror	1,750,200	0.68	-	-
2	Medeze Group PCL ³	-	-	1,750,200	0.68
3	Medeze Holding Company Limited ⁴	-	-	1,750,200	0.68
4	Veerapol Khemarangsang ⁵	-	-	1,750,200	0.68
5	Medeze International Limited ⁶	-	-	1,750,200	0.68

Notes:

- The deemed interest arises by virtue of Section 4 of the Securities and Futures, Act, Chapter 289 of Singapore.
- Calculated based on 256,307,744 Shares (excluding treasury shares) and rounded to the nearest two (2) decimal places.
- Medeze Group PCL is the parent company of the Offeror and is entitled to exercise or control the exercise of not less than 20% of the votes attached to the voting shares in the Offeror. Accordingly, Medeze Group PCL has a deemed interest in the Shares held by the Offeror.
- Medeze Holding Company Limited is entitled to exercise or control the exercise of not less than 20% of the votes attached to the voting shares in Medeze Group PCL, which is the parent company of the Offeror. Accordingly, Medeze Holding Company Limited has a deemed interest in the Shares held by the Offeror.
- Veerapol Khemarangsang is entitled to exercise or control the exercise of not less than 20% of the votes attached to the voting shares in Medeze Group PCL, which is the parent company of the Offeror. Accordingly, Veerapol Khemarangsang has a deemed interest in the Shares held by the Offeror. For completeness, Veerapol Khemarangsang is also the Chief Executive Officer of Medeze Group PCL, a director of Medeze Holding Company Limited and the sole director and shareholder of Medeze International Limited. Medeze International Limited is deemed to be interested in the 1,750,200 Shares held by the Offeror. Accordingly, Veerapol Khemarangsang is also deemed to be interested in the Shares held by the Offeror by way of him being the sole shareholder of Medeze International Limited.
- Medeze International Limited is entitled to exercise or control the exercise of not less than 20% of the votes attached to the voting shares in Medeze Holding Company Limited, which is entitled to exercise or control the exercise of not less than 20% of votes attached to the voting shares in the Medeze Group PCL, which in turn is the parent company of the Offeror. Accordingly, Medeze International Limited has a deemed interest in the Shares held by the Offeror.

Appendix 3

Details of Dealings in Shares by Relevant Persons in the Six Months preceding the Offer Announcement Date

Name	Relationship to Offeror	Date	No. of Shares Bought	No. of Shares Sold	Transaction Price per Share (S\$)	%
Offeror	-	25 February 2025	21,700	-	0.166982	0.00020
		4 March 2025	364,400	-	0.159959	0.00004
		5 March 2025	205,600	-	0.1600	0.00390
		6 March 2025	39,500	-	0.1600	0.00156
		10 March 2025	26,200	-	0.1600	0.00043
		11 March 2025	21,500	-	0.1600	0.05002
		14 March 2025	105,000	-	0.1600	0.07425
		17 March 2025	191,100	-	0.1600	0.07483
		18 March 2025	31,300	-	0.1600	0.08501
		8 April 2025	217,900	-	0.159982	0.01221
		9 April 2025	191,800	-	0.1600	0.07456
		10 April 2025	190,300	-	0.1600	0.04097
		11 April 2025	128,200	-	0.159619	0.00839
		14 April 2025	1,100	-	0.1600	0.01022
		15 April 2025	4,000	-	0.1600	0.01541
		16 April 2025	10,000	-	0.1600	0.08022
		17 April 2025	100	-	0.1600	0.14217
		21 April 2025	500	-	0.1600	0.00847